Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma. This is an ASCO Meeting Abstract from the 2019 ...
aDivision of Hematology and Medical Oncology, VA Portland Health Care System and Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results